Brand: ProteoGenix

Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade

PX-TA1040
Quality Chart

Clonality:: Monoclonal Antibody
Isotype:: IgG1, kappa

$238.00

+ 238 loyalty points

Size Size

100ug $238.00
1MG $482.00

First Name This field is required. Last Name This field is required. Email This field is required. Company This field is required. Country This field is required. State This field is required.

In Stock
Wide range of unique reagents
Fast worldwide delivery

SDS-PAGE for Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb

Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade

Product name	Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade
Source	CAS 214745-43-4
Species	Humanized
Purity	>85%
Buffer	PBS buffer PH7.5
Delivery condition	Blue ice (+4°C)
Delivery Time	3-5 days if in stock; 3-5 weeks if production needed
Storage condition	store at -80°C
Brand	ProteoGenix
Applications	ELISA,WB
Aliases /Synonyms	Efalizumab,hu1124,ITGAL, CD11a,anti-ITGAL, CD11a
Reference	PX-TA1040
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype	IgG1-kappa
Clonality	Monoclonal Antibody

Product name	Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade
Source	CAS 214745-43-4
Species	Humanized
Purity	>85%
Buffer	PBS buffer PH7.5
Delivery condition	Blue ice (+4°C)
Delivery Time	3-5 days if in stock; 3-5 weeks if production needed
Storage condition	store at -80°C
Brand	ProteoGenix
Applications	ELISA,WB,,,
Aliases /Synonyms	Efalizumab,hu1124,ITGAL, CD11a,anti-ITGAL, CD11a
Reference	PX-TA1040
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype	IgG1-kappa
Clonality	Monoclonal Antibody

General information on Anti-ITGAL/CD11a(Homo sapiens) (Efalizumab) Monoclonal Antibody

Efalizumab is a recombinant monoclonal antibody to Human CD11A. Under the trade name Raptiva, it is a drug that was previously used to treat autoimmune diseases and was originally used to treat psoriasis. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and inhibits lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab has been associated with fatal brain infections.

SDS-PAGE for Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb

Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

There are no reviews yet.

Be the first to review “Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Your rating *

In which application did you use the antibody? *

Did it work in your application? * Yes No

Your review *

Name *

Email *

Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade

Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade

General information on Anti-ITGAL/CD11a(Homo sapiens) (Efalizumab) Monoclonal Antibody

SDS-PAGE for Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb

Related products

ITGAL recombinant protein

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

Recently viewed products

Can’t find what you need?

Cart (0 Items)

Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade

Specifications Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade

Description

General information on Anti-ITGAL/CD11a(Homo sapiens) (Efalizumab) Monoclonal Antibody

Documents

QC & Validation

SDS-PAGE for Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb

Reviews

Related products

ITGAL recombinant protein

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

Recently viewed products

Can’t find what you need?

Cart (0 Items)

Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade